Intercession variability in single-breath diffusing capacity in diabetics without overt lung disease

American Journal of Respiratory and Critical Care Medicine

Volumn 178, Issue 3, 2008, Pages 225-232

  Drummond, Michael B ^a   Schwartz, Pamela F ^b   Duggan, William T ^b   Teeter, John G ^b   Riese, Richard J ^b   Ahrens, Richard C ^c   Crapo, Robert O ^d   England, Richard D ^b   MacIntyre, Neil R ^e   Jensen, Robert L ^d   Wise, Robert A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diffusing capacity; Inhaled human insulin; Intersession variability; Methodology; Respiratory function testing

Indexed keywords

RECOMBINANT HUMAN INSULIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST; FEMALE; HUMAN; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; INSULIN DEPENDENT DIABETES MELLITUS; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; REFERENCE VALUE; REPRODUCIBILITY;

ADULT; AGED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DIFFUSING CAPACITY; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; RESPIRATORY FUNCTION TESTS;

EID: 48249156558     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200801-090OC     Document Type: Article

References (33)

1. Martinez FJ, Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3:315-321.
2. Nakano M, Hasegawa H, Takada T, Ito S, Muramatsu Y, Satoh M, Suzuki E, Geiyo F. Pulmonary diffusion capacity in patients with systemic lupus erythematosus. Respirology 2002;7:45-49.
3. Takeda S, Yasunobu F, Kadota Y, Koma M, Maeda H, Kawamura S ,Matsubara Y. Fall in diffusion capacity associated with induction therapy for lung cancer: a predictor of postoperative complications? Ann Thorac Surg 2006;82:232-236.
4. Stam H, Splinter T, Versprille A. Evaluation of diffusing capacity in patients with restrictive lung disease. Chest 2000;117:752-757.
5. Proudman S, Stevens W, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Int Med J 2007;37:485-494.
6. Jenson RL, Teeter JG, England RD, White HJ, Pickering EH, Crapo RO. Instrument accuracy and reproducibility in measurements of pulmonary function. Chest 2007;132:388-395.
7. Jenson RL, Teeter JG, England RD, Howell HM, White HJ, Pickering EH, Crapo RO. Sources of long-term variability in measurement of lung function. Chest 2007;132:389-402.
8. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Griten CPM, Gustafsson P, Hankinson J, et al.; American Thoracic Society/European Respiratory Society Task Force. Standardisation of lung function testing: interpretative strategies for lung function testing. Eur Respir J 2005;26:948-968.
9. Hathaway E, Tashkin D, Simmons M. Intraindividual variability in serial measurements of DLCO and alveolar volume over one year in eight healthy subjects using three independent measuring systems. Am Rev Respir Dis 1989;140:1818-1822.
10. Wanger J, Irvin C. Comparability of pulmonary function results from 13 laboratories in a metropolitan area. Respir Care 1991;36:1375-1382.
11. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 1995;152:2185-2198.
12. Punjabi NM, Shade D, Patel AM, Wise RA. Measurement variability in single-breath diffusing capacity of the lung. Chest 2003;123:1082-1089.
13. Hollander PA, Blonde L, Rowe R, Mehta A, Milburn J, Hershon K, Chiasson J, Levin S. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2356-2362.
14. Quattrin T, Bélanger A, Bohannon NJV, Schwartz SL; for the Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type I diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622-2627.
15. Skyler JS, Weinstock RS, Raskin P, Yale J, Barrett E, Gerich J, Gerstein H; for the Inhaled Insulin Phase III Type I Diabetes Study Group. Use of inhaled insulininabasal/bolus insulin regimenin subjects with type 1 diabetes: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630-1635.
16. Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan S-P, Cefalu WT. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005;142:549-558.
17. Skyler JS, Cefalu WT, Kourides IA, Landschulz W, Balagtas C, Cheng S, Gelfand R; for the Inhaled Insulin Phase 2 Study Group. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof-of-concept study. Lancet 2001;357:331-335.
18. Cefalu WT, Skyler JS, Kourides IA, Landschulz W, Balagtas C, Cheng S, Gelfand R; for the Inhaled Insulin Study Group. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001;134:203-207.
19. Weiss SR, Cheng S-L, Kourides IA, Gelfand R, Landschulz W; for the Inhaled Insulin Phase II Study Group. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Ann Intern Med 2003;163:2277-2282.
20. DeFronzo RA, Bergenstal RM, Cefalu WT, Pullman J, Lerman S, Bode BW, Phillips LS; for the Exubera Phase III Study Group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. Diabetes Care 2005;28:1922-1928.
21. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006;29:1282-1287.
22. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 2006;29:1818-1825.
23. Wise RA, Teeter JG, Jensen RL, England R, Schwartz P, Giles D, Ahrens R, MacIntyre N, Riese R, Crapo R. Standardization of the single-breath diffusing capacity (DLCO) in a multicenter clinical trial. Chest 2007;132:1191-1197.
24. Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W; for the Inhaled Human Insulin Type 1 Diabetes Study Group. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007;30:579-585.
25. Heise T, Bott S, Tusek C, Stephan J-A, Kawabata T, Finco-Kent D, Liu C, Krasner A. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamics study. Diabetes Care 2005;28:2161-2169.
26. Lange P, Klioze S, Foyt H, Ogawa M, St. Aubin L, Duggan W, Riese R, Teeter J; for the Exubera 1029 Study Group. Pulmonary function of inhaled human insulin (Exubera®) in patients with type 2 diabetes: results from a 2-year study using standardized methodology [abstract E4257]. Eur Respir J 2006;28:742s.
27. Norwood P, Dumas R, Cefalu W, Yale JF, England R, Riese R, Teeter J. Randomized study to characterize glycemic control and short-term pulmonary function in patients with type 1 diabetes receiving inhaled human insulin (Exubera). J Clin Endocrinol Metab 2007;92:2211-2214.
28. Miller A, Thornton JC, Warshaw R, Anderson H, Teirstein A, Selikoff I. Single-breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state: predicted values, lower limits of normal and frequencies of abnormalities by smoking history. Am Rev Respir Dis 1983;127:270-277.
29. Crapo RO, Morris AH, Clayton PD, Nixon C. Lung volumes in healthy nonsmoking adults. Eur Physiopathol Respir 1982;18:419-425.
30. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187.
31. Ljubic S, Metelko Z, Car N, Roglic G, Drazic Z. Reduction of diffusion capacity for carbon monoxide in diabetic patients. Chest 1998;114: 1033-1035.
32. Guvener N, Tutuncu NB, Akcay S, Eyuboglu F, Gokcel A. Alveolar gas exchange in patients with type 2 diabetes mellitus. Endocr J 2003;50: 663-667.
33. Sherrill DL, Enright PL, Kaltenborn WT, Lebowitz MD. Predictors of longitudinal change in diffusing capacity over 8 years. Am J Respir Crit Care Med 1999;160:1883-1887.